Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of Tuesday, October 6, 2026.
RETURN ON EQUITY (ROE)
N/A
Market Cap
$867.60M
Return on Equity (ROE)
-33.06%
TTM Avg
-24.59%
3Y Avg
-41.17%
5Y Avg
-18.72%
Market Cap
$856.30M
Return on Equity (ROE)
-34.83%
TTM Avg
-64.71%
3Y Avg
-59.77%
5Y Avg
-96.53%
Market Cap
$852.55M
Return on Equity (ROE)
-28.46%
TTM Avg
-48.75%
3Y Avg
-33.66%
5Y Avg
-33.66%
Market Cap
$844.28M
Return on Equity (ROE)
-97.08%
TTM Avg
-96.94%
3Y Avg
-22.72%
5Y Avg
-22.72%
Market Cap
$837.43M
Return on Equity (ROE)
-37.38%
TTM Avg
-29.74%
3Y Avg
-41.86%
5Y Avg
-72.28%
Market Cap
$903.13M
Return on Equity (ROE)
-24.02%
TTM Avg
-108.12%
3Y Avg
-89.93%
5Y Avg
-68.76%
Market Cap
$819.44M
Return on Equity (ROE)
-13.30%
TTM Avg
11.91%
3Y Avg
154.09%
5Y Avg
54.89%
Market Cap
$915.95M
Return on Equity (ROE)
23.86%
TTM Avg
-5.16%
3Y Avg
-37.28%
5Y Avg
-22.23%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Apnimed, Inc. (APMD) | $866.15M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $867.60M | -33.06% | -24.59% | -41.17% | -18.72% |
| Jade Biosciences, Inc. (JBIO)vs › | $856.30M | -34.83% | -64.71% | -59.77% | -96.53% |
| Beta Bionics, Inc. (BBNX)vs › | $852.55M | -28.46% | -48.75% | -33.66% | -33.66% |
| Alumis Inc. (ALMS)vs › | $844.28M | -97.08% | -96.94% | -22.72% | -22.72% |
| Ardelyx, Inc. (ARDX)vs › | $837.43M | -37.38% | -29.74% | -41.86% | -72.28% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.13M | -24.02% | -108.12% | -89.93% | -68.76% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $819.44M | -13.30% | 11.91% | 154.09% | 54.89% |
| Bioventus Inc. (BVS)vs › | $915.95M | 23.86% | -5.16% | -37.28% | -22.23% |
| InMode Ltd. (INMD)vs › | $812.20M | 12.32% | 19.75% | 23.44% | 27.16% |
ROE
N/A
ROA
N/A
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
